Yanan Zhu
Stock Analyst at Wells Fargo
(2.86)
# 1,449
Out of 5,111 analysts
84
Total ratings
40%
Success rate
0.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Overweight | $80 → $60 | $21.89 | +174.10% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Equal-Weight | $17 → $12 | $9.12 | +31.58% | 7 | Nov 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $50 → $45 | $22.31 | +101.70% | 7 | Nov 5, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $48 → $72 | $34.03 | +111.58% | 7 | Nov 3, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $42 → $20 | $7.13 | +180.50% | 9 | Oct 23, 2025 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $2.51 | +59.36% | 7 | Sep 3, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Overweight | $45 | $34.22 | +31.50% | 1 | Aug 25, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $77 → $82 | $78.37 | +4.63% | 3 | Aug 22, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $16 → $12 | $1.71 | +601.75% | 4 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $7.5 → $8 | $5.82 | +37.46% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2.5 | $1.09 | +129.36% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.60 | +212.50% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $2.25 | +522.22% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $75 | $71.97 | +4.21% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $26.76 | +161.58% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $4.42 | +126.24% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $32.97 | +21.32% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $55.97 | +16.13% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $8.38 | +258.00% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.44 | +807.03% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $4.36 | +10,221.10% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $851.42 | -61.71% | 1 | Feb 2, 2021 |
uniQure
Nov 12, 2025
Maintains: Overweight
Price Target: $80 → $60
Current: $21.89
Upside: +174.10%
Intellia Therapeutics
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $17 → $12
Current: $9.12
Upside: +31.58%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $22.31
Upside: +101.70%
RAPT Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $48 → $72
Current: $34.03
Upside: +111.58%
Arcturus Therapeutics Holdings
Oct 23, 2025
Maintains: Overweight
Price Target: $42 → $20
Current: $7.13
Upside: +180.50%
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $2.51
Upside: +59.36%
NewAmsterdam Pharma Company
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $34.22
Upside: +31.50%
Ionis Pharmaceuticals
Aug 22, 2025
Maintains: Overweight
Price Target: $77 → $82
Current: $78.37
Upside: +4.63%
Metagenomi
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $1.71
Upside: +601.75%
Taysha Gene Therapies
Aug 13, 2025
Maintains: Overweight
Price Target: $7.5 → $8
Current: $5.82
Upside: +37.46%
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $1.09
Upside: +129.36%
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.60
Upside: +212.50%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $2.25
Upside: +522.22%
Aug 8, 2025
Maintains: Overweight
Price Target: $70 → $75
Current: $71.97
Upside: +4.21%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $26.76
Upside: +161.58%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $4.42
Upside: +126.24%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $32.97
Upside: +21.32%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $55.97
Upside: +16.13%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $8.38
Upside: +258.00%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.44
Upside: +807.03%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $4.36
Upside: +10,221.10%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $851.42
Upside: -61.71%